Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects

Next Previous
Trial Profile

A Randomized, Single-blind, Single-dose, 3-arm, Parallel Group Study to Determine the Pharmacokinetic Similarity of ABP 710 and Infliximab (Remicade 'Registered Trademark') in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Inflammation; Rheumatic disorders
  • Focus Pharmacokinetics
  • Sponsors Amgen

Most Recent Events

  • 01 Nov 2017 Primary endpoint has been met. (The primary objective of this study is to determine the PK similarity (as assessed principally by AUCinf) of ABP 710 following a 5 mg/kg intravenous (IV) infusion relative to that of a 5 mg/kg IV infusion ofinfliximab (US) or a 5 mg/kg IV infusion of infliximab (EU)) as per results presented at the 25th United European Gastroenterology Week
  • 01 Nov 2017 Results presented at the 25th United European Gastroenterology Week
  • 17 Jun 2017 Results comparing pharmacokinetics of ABP-710 and infliximab sourced from the European Union (n=98), presented at the 18th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top